Sign in to view content

Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation

Tarek S. Hassan, MD, FASRS

Video
Published 2020

Related

Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more